On January 2, AstraZeneca and Merck jointly announced that their PARP inhibitor Lynparza (English trade name: Lynparza, generic name: Olaparib) has been approved in China for the adjuvant treatment of adult patients with early high-risk breast cancer carrying harmful or suspected harmful germline BRCA mutations (gBRCAm) and negative for human epidermal growth factor receptor 2 (HER2) who have received neoadjuvant or adjuvant chemotherapy.
利普卓在华获批用于gBRCA突变HER2阴性早期高风险乳腺癌的辅助治疗
Lynparza has been approved in China for adjuvant treatment of early high-risk breast cancer with gBRCA mutations and HER2 negative.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.